← Back to Search

Chemotherapy

Rituxan/Abraxane for Malignant Melanoma

Phase 2
Waitlist Available
Led By Edward F. McClay, M.D.
Research Sponsored by California Cancer Assocaties for Research & Excellence
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 2 years
Awards & highlights

Study Summary

The purpose of this research study is to test an experimental combination of drugs to determine if they can cause shrinkage or even complete disappearance of your melanoma. The two drugs being tested in combination are Rituxan and Abraxane

Eligible Conditions
  • Malignant Melanoma
  • Melanoma

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~2 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and 2 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Overall response as determined by a Percent change (%) in the sum of the diameters of target lesions.
Secondary outcome measures
Response rate as Percent change in diameter (mm) of target lesions

Side effects data

From 2013 Phase 4 trial • 40 Patients • NCT00782821
50%
CTCAE Grade 1 Diarrhea
30%
CTCAE Grade 1 Nausea/Vomiting
30%
CTCAE Grade 2 Nausea/Vomiting
30%
CTCAE Grade 2 Diarrhea
20%
CMV Invasive Disease
20%
BKV Viremia
20%
CMV Viremia
10%
CTCAE Grade 3 Diarrhea
10%
CMV +/- Status
10%
CTCAE Grade 3 Nausea/Vomiting
100%
80%
60%
40%
20%
0%
Study treatment Arm
RATG/Rituxan/Velcade
RATG/Rituxan
Rabbit Antithymocyte Globulin (RATG)
RATG/Velcade

Trial Design

1Treatment groups
Experimental Treatment
Group I: Rituxan/AbraxaneExperimental Treatment1 Intervention
This is a single arm study. All patients recieve treatment.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Paclitaxel
FDA approved

Find a Location

Who is running the clinical trial?

California Cancer Assocaties for Research & ExcellenceLead Sponsor
Edward F. McClay, M.D.Principal InvestigatorCalifornia Cancer Assocaties for Research & Excellence

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Rituxan and Abraxane for the Treatment of Patients With Inoperable Stage III and IV Malignant Melanoma
Edward F. McClay, M.D. 2014. "Rituxan and Abraxane for the Treatment of Patients With Inoperable Stage III and IV Malignant Melanoma". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT02142335.
All > Malignant Melanoma
~2 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top